Administration, regardless of being subcutaneous, intramuscular, or oral, requires sterile techniques and proper handling to prevent infection or contamination
When approved options may arrive CagriSema may reach the market within the next one to two years based on current trial timelines and regulatory trajectories
The condition typically progresses through stages, beginning with simple steatosis (fat accumulation alone), potentially advancing to non-alcoholic steatohepatitis (NASH) where inflammation develops, and in some cases progressing to fibrosis, cirrhosis, or hepatocellular carcinoma
6, repeat steps4
Before we dive into how it's administered, let's quickly recap what we're working with
Studies show the peptide markedly decreases activation of astrocytes and microgliathe brain's primary immune cells whose chronic activation contributes to neurodegeneration